Citations

Clear

116 citation(s) found for "Schmitt, J".

Clinical considerations for immune dysregulation and immunodeficiency in Down syndrome
Gans, Melissa , Wyke, Matthew , Manothummetha, Kasama , Lesmana, Harry , Squire, Jacqueline D. , Schmitt, Erica G. , Ale, Hanadys , Shin, Joyce , Chaimowitz, Natalia , Camacho, Juanita Valdes , Wyke, Matthew , Manothummetha, Kasama , Lesmana, Harry , Squire, Jacqueline , Lopes, Joao Pedro , Schmitt, Erica G , Ale, Hanadys , J Shin, Junghee , Chaimowitz, Natalia , Baloh, Carolyn , Bogunovic, Dusan , Espinosa, Joaquin , Gans, Melissa D.

Mayo Clinic

Journal of Human Immunity | July 15, 2026 | Volume: 2 | Issue: 5 | Pages: No page available

10.70962/jhi.20260052 | PMID 42459548 Get It

Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), is characterized by lifelong immune dysregulation leading to high rates of autoimmune disorders, elevated risk of complications from infections, immune hypersensitivity, and a unique form of immunodeficiency. It is now appreciated that DS shares key hallmarks with interferonopathies, with vast remodeling of all branches of the immune system, hypercytokinemia, and widespread autoantibody production. Here within, we review the existing literature with an emphasis on clinical considerations toward monitoring, management, and therapeutic opportunities. We highlight recent research advances that illuminate diagnostic approaches to evaluate immune dysregulation in DS. We also discuss the evidence supporting specific immunomodulatory strategies that could have multidimensional benefits in this population, including JAK inhibitors, intravenous immunoglobulin, and B cell–depleting agents.
Accuracy of the rapid‐response electroencephalography's Automated Seizure Burden Estimator: A follow‐up validation study of version 8 ( AccuRASE II )
Sheikh, Zubeda , Fong, Michael W K , Dhakar, Monica B. , Fang, Wei , Ayub, Neishay , Bacic, Janine , Haider, Hiba A. , Foreman, Brandon , Gilmore, Emily J. , Mizrahi, Moshe , Osman, Gamaleldin , Sheikh, Zubeda B , Dhakar, Monica B , Molino, Janine , Karakis, Ioannis , Schmitt, Sarah E , Osman, Gamaleldin , Yoo, Ji Yeoun , Hirsch, Lawrence J , Haider, Hiba A , Ayub, Neishay , Gilmore, Emily , Foreman, Brandon , Karakis, Ioannis , Yoo, Ji Yeoun , Hirsch, Lawrence J.

Mayo Clinic

Epilepsia | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70352 | PMID 42347801 Get It

Abstract Objective Ceribell Inc.'s point‐of‐care electroencephalographic (EEG) system and artificial intelligence‐based Automated Seizure Burden Estimator (ASBE; ClarityPro) have US Food and Drug Administration clearance for diagnosing electrographic status epilepticus (ESE). The AccuRASE study using ASBE version 6 (V6) showed high negative predictive value (NPV) but limited sensitivity and positive predictive value (PPV) at certain thresholds. Version 8 (V8) is the updated algorithm trained with additional EEG samples. Methods We tested V8 on the previously used rapid‐response EEG test dataset (not used to train V8). Sensitivity, specificity, PPV, and NPV were compared against blinded expert annotations. ESE, ESE and possible ESE (ESE/pESE), electrographic seizures (ESz), and Esz with highly epileptiform patterns (Esz/HEPs) at burden thresholds of >1%, >10%, >20%, >50%, and >90% were analyzed. Additionally, we evaluated the built‐in ESE and ESE/pESE alerts (≥90% over 5 min, ≥20% over 1 h, or ≥10 continuous minutes of seizure). Results V8 showed 100% sensitivity at lower thresholds (>10%–20%) for ESE (V6 .86), without a specificity loss (V8 .9 vs. V6 .85), and retained NPV (V8 1.0 vs. V6 .99). Sensitivity at 50% threshold was .86 for ESE (V6 .71), and specificity was .94 (V6 .91); PPV for ESE was 30% for ESE and 80% for ESE/pESE. The specificity for ESE remained high for 90% burden (V8 .96, V6 .97) but the sensitivity dropped (.29 vs. V6 .43). Sensitivity was lower for ESz/HEPs (.54 → .44 at >10% threshold), although the algorithm is not designed to detect HEPs. Built‐in alert analysis showed significantly improved sensitivity for ESE (.57 → .86); specificity and NPV remained high (>.94). Significance ASBE V8 showed meaningful improvements in sensitivity, continued excellent NPV, and improved built‐in alert accuracy for ESE and ESE/pESE. The best seizure burden threshold for ruling out ESE now is 20% (vs. 10% with V6) and that for ruling in ESE/pESE with reasonable certainty is 50% (vs. 90% with V6).
Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma
Wang, Chang , 吴得红, Tzankov, Alexandar, Møller, Michael , Visco, Carlo , Hsi, Eric D. , Zhao, Xiaoxian , Lv, Beibei, Wang, Bangchen , Yao, Shuna, Chiu, April , Dybkær, Karen , Bhagat, Govind , Montes-Moreno, Santiago, Pan, Zenggang , Bernal‐Mizrachi, Leon , Krieken, J Han JM van, Choi, William W.L., Tam, Wayne , Chen, Weina , Ponzoni, Maurilio, Ferreri, Andrés J.M. , Khajouei, Farzaneh , Sikkink, Kristin , Schmitt, Anthony D. , Xu-Monette, Zijun Y , Møller, Michael Boe , Visco, Carlo , Hsi, Eric D , Lv, Beibei , Wang, Bangchen , Chiu, April , Dybkaer, Karen , Bhagat, Govind , Chen, Weina , Parsons, Benjamin M , Khajouei, Farzaneh , Sikkink, Kristin , Li, Yong , Young, Ken H , Xu‐Monette, Zijun Y. , Tzankov, Alexandar , Cao, Xin , Zu, Youli , Montes‐Moreno, Santiago , Krieken, J. Han van , Ponzoni, Maurilio , Parsons, Benjamin M. , Li, Yong , Hastie, Alex R. , Young, Ken H.

Mayo Clinic

Blood Advances | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026019675 | PMID 42308239 Get It

Diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma, arises from various pathogenic mechanisms including gene translocations and fusions. Detection of gene rearrangements using fluorescence in situ hybridization (FISH) is a standard practice for DLBCL diagnosis and guides treatment decisions. High-throughput chromosome conformation capture (Hi-C) DNA sequencing is a next-generation sequencing-based technology to identify genome-wide rearrangements using a single assay. In this study, Hi-C sequencing was performed using FFPE tissues from 159 patients with DLBCL, and identified 746 cancer genes at or proximal to the rearrangement breakpoints with a total of 1903 occurrences. Focusing on clinically important rearrangements, Hi-C detected 102 rearrangements of MYC, BCL2, and/or BCL6 in 92 patients and revealed the fusion partners, including 25 rearrangements missed by FISH. Causes of FISH negative results included FISH-cryptic breakpoints, complex or faint FISH signals, low percentage of FISH positivity, and issues related to tissue fixation. Moreover, in 20 patients (12.6%), Hi-C sequencing detected 22 rearrangements characteristic of other lymphoma types, including CCND1 rearrangements that could lead to reclassification as mantle cell lymphoma. Survival analysis for genome-wide rearrangements using machine learning models identified MYC, PD-L1, CCND1, BCL2, NTRK1/PRCC, RRAS, and FANCE rearrangements with significant prognostic effects in the DLBCL cohort. In conclusion, Hi-C sequencing detects gene rearrangements crucial for diagnosis in an unbiased and molecular manner and showed high sensitivity and specificity in our study. These advantages of Hi-C sequencing offer help to improve the workflow of clinical pathology laboratories, diagnostic precision, and treatment of large B-cell lymphoma.
Development of a Core Outcome Domain Set for Facial Aging
Dirr, McKenzie A. , Ahmed, Areeba, Schlessinger, Daniel I., Lazaro-Camp, Vanessa, Smith, SJ, Gullapalli, Thanvi, Dragovic, Doroteja, Chang, Joycie, Zhang, Elizabeth, Alam, Murad, Group, Facial Aging Core Outcome Domain Set Study, Anvery, Noor , Kang, Bianca Y. , Wong, Clarissa, Iyengar, Sanjana, Yanes, Arianna F. , Cotseones, Jill, Ashchyan, Hovik J. , Patel, P. M., Sheikh, Umar A., Franklin, Matthew , Hanna, Courtney, Chiren, Sarah G., Schmitt, J, Furlan, Karina C., Alexiades, Macrene, Alhusayen, Raed, Alster, Tina S. , Beer, Kenneth, Bertucci, Vince , Bloom, Jason D. , Briceño, César A., Bucay, Vivian, Butterwick, Kimberly J., Hugues, Cartier, Casabona, Gabriela, Connolly, Karen , Cox, Sue Ellen , Darmanescu, Monica, Boulle, Koenraad De , Desai, Shraddha, Donofrio, Lisa, Dover, Jeffrey S., Draelos, Zoe, Eisen, Daniel B. , El-Domyati, Moetaz, El-Garem, Yehia, Fischer, John, Fitzgerald, Rebecca, GALADARI, Hassan, Gladstone, Hayes B., Goldman, Mitchel P., Goodman, Greg J., Hanke, C. William , Humphrey, Shannon, Ibrahim, Sherrif F., Jagdeo, Jared, Karen, Julie, Kauvar, Arielle, Ag, Kibbi, KIM, JENNY, Lacerda, D T D, Lask, G, Lopez, Grace M., Lupo, Mary P. , Mariwalla, Kavita , Matarasso, Seth, Mekokishvili, L, Narins, Rhoda S., Ogilvie, P, Orringer, Jeffrey S. , Osaki, Tammy H. , Ozog, David, Pacheco, Theresa, Polder, Kristel, Rossi, Anthony M, Sadick, Neil, Saedi, Nazanin, Schlessinger, Joel, Sharad, Jaishree , Shenoy, SuchitraM, Sinclair, Rd, Solish, Nowell, Piansay‐Soriano, Miriam Emily , Sulyman, Omotara , Szeimies, Rolf‐Markus , Tanzi, Elizabeth L., Taub, Amy Forman , Taylor, Mark B., Thomas, J. Regan, Torezan, Luis, Tosti, Antonella, Touma, Dany, Almeida, Ada Regina Trindade de , Vedamurthy, Maya , Viana, Giovanni, Waldman, Abigail, Weinkle, Susan, Weiss, Robert, Poon, Emily, Cartee, Todd V. , Sobanko, Joseph F. , Eisen, Daniel B. , Ahmed, Areeba , Schlessinger, Daniel Isaac , Lazaro-Camp, Vanessa J, Christensen, Rachel E. , Ibrahim, Sarah A. , Cotseones, J.K., Umar, Sheikh Ahmad , Furlan, Karina Colossi , Alexiades, Macrene , Alhusayen, Raed , Beer, Kenneth Robert, Briceño, César Augusto , Bucay, Vivian , Casabona, Gabriela , Cotofana, Sebastian , Desai, Shraddha , Dover, Jeffrey S. , Draelos, Zoe Diana , Eisen, Daniel B., El-Domyati, Moetaz M. , El-Garem, Yehia, Fitzgerald, Rebecca, Friedmann, Daniel P. , Galadari, Hassan , Gladstone, Hayes B., Goldman, Mitchel P. , Goodman, Greg , Green, Jeremy B. , Halachmi, Shlomit , Humphrey, Shannon , Jagdeo, Jared R. , Jiang, Shang I. Brian , Kauvar, Arielle N.B. , Kibbi, Abdul‐Ghani , Kim, John V. S., LASK, GARY P., Matarasso, Seth L., Narins, Rhoda S., Ogilvie, Patricia , Osaki, Tammy H. , Pacheco, Theresa , Polder, Kristel D., Saedi, Nazanin, Shenoy, Manjunath , Sinclair, Rod, Solish, Nowell , Torezan, Luís , Tosti, Antonellá , Waldman, Abigail , Weiss, Robert, Maher, Ian A. , Kirkham, Jamie J

Mayo Clinic

JAMA Dermatology | June 17, 2026 | Volume: 162 | Issue: 8 | Pages: 829

10.1001/jamadermatol.2026.1697 | PMID 42307924 Get It

Importance Currently, there are no standardized outcome domains or measures in clinical trials for facial aging. Heterogeneity in outcome domains and measurement instruments across clinical trials creates difficulty in directly comparing interventions, determining superior therapies, and developing high-quality meta-analyses. Objective To develop a core outcome set (COS) of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging. Evidence Review PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched from September 2005 to September 2015. An updated search of the same databases was performed from September 2015 to February 2026. Studies were included if (1) they were randomized clinical trial or controlled clinical trial in design, (2) they assessed the efficacy or safety of an intervention for facial aging, (3) they were published in English, and (4) they involved human participants. Complementary sources, including patient interviews, were used to capture further relevant outcomes. Two rounds of Delphi surveys, followed by consensus meetings, were used to identify outcome domains considered most important by both patient and physician stakeholders. Findings The final COS consists of 6 outcome domains: (1) overall convenience of treatment; (2) time to return to normal work and social activity; (3) overall assessment of focused area of treatment (at the point in time when treatment is expected to provide peak benefit); (4) duration of treatment effect; (5) severity of persistent local or systemic adverse events, including pigmentary change, skin texture change, delayed healing, scarring, and serious adverse events; and (6) patient satisfaction with treatment. Conclusions and Relevance The 6 outcome domains identified through a Delphi consensus are recommended for reporting in future facial aging trials to ensure that outcomes that matter most to patients and clinicians are measured and that results are comparable across interventions.
Virtual AI-informed immunocyte profiling (VAIP) from H&E as a predictor of multi-cancer prognosis.
Jana, Mayukhmala , Aggarwal, Arpit, Shanbhogue, Nikhil, Pathak, Tilak, Toro, Paula , Lewis, James S., Wasman, Jay, Teknos, Theodoros N., Pan, Quintin, Shi, Qiuying , Schmitt, Nicole Cherie, Saba, Nabil F., Oršulić, Sandra , Bazzaro, Martina , Corredor, Germán, Madabhushi, Anant, Aggarwal, Arpit , Badve, Sunil , Thorat, Mangesh A. , Lewis, James S. , Pan, Quintin , Schmitt, Nicole C. , Steward-Tharp, Scott Michael , Saba, Nabil F. , Corredor, Germán

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 3118-3118

10.1200/jco.2026.44.16_suppl.3118 Get It

3118 Background: Improved risk stratification is critically needed across multiple cancers to guide treatment decisions. This includes reducing overtreatment in Ductal Carcinoma in Situ (DCIS), addressing late recurrence risk in estrogen receptor-positive/lymph node-negative (ER+/LN-) breast cancer (BC), and refining prognosis in head & neck squamous cell carcinomas (HNSCC), and high-grade serous ovarian carcinoma (HGSOC). Tumor-infiltrating lymphocytes (TILs) reflect anti-tumor immunity, whereas tumor-associated macrophages (TAMs) polarize toward anti-tumor M1-like (CD68+) or immunosuppressive M2-like (CD163+) phenotypes. Integrating TILs with TAM polarization markers may better capture inflammatory balance and improve outcome prediction. We developed a hematoxylin and eosin (H&E)-only AI method (VAIP) to quantify TILs and virtual CD68/CD163 TAMs to develop multi-cancer based potential prognostic models. Methods: TILs were detected on H&E with HoVer-UNet, and virtual CD68 and CD163 macrophages were inferred with VISTA. In cancer regions, we computed cell densities and immune-balance ratios and trained cancer-specific Cox models with compact feature sets (DCIS 6; HGSOC 7; ER+ 4; HNSCC 4). Prognostic stratification used disease-free survival (DFS) for DCIS (N=273), HGSOC (training N=165, independent test N=220), and ER+ BC (training N=144, test N=622), and overall survival (OS) for HNSCC (N=77), reflecting clinical endpoints. Evaluation used cross-validation for cohorts without an external test set (DCIS, HNSCC) and independent training and testing when independent cohort was available (HGSOC, ER+). Results: Risk stratification performance across cancer types is in Table 1. The DCIS model used 6 features, largely TIL-macrophage contrast ratios (TIL/M2, TIL/M1). HGSOC used 7 features with a similar ratio-heavy immune-balance signature, plus macrophage-normalized density and polarization metrics (e.g., M1/N, M/N). In contrast, ER+ BC and HNSCC achieved best performance with 4 features dominated by macrophage measures, particularly M2 density and the M1/M2 ratio. Across sites, CD163-related macrophage metrics and immune-balance ratios were consistently informative. Conclusions: Integrating H&E-visible TILs with virtual CD68/CD163 TAMs enables fully automated, H&E-only prognostic biomarkers that stratify OS and DFS across multiple cancers, demonstrating consistent prognostic value in DCIS, ER+ BC, HGSOC, and HNSCC. These findings support further study of this histomorphometric risk classifier through broader external and prospective validation. Performance across cancer types. Cancer Type Cohort C-index HR [95% CI] p-value DCIS All 0.616 1.76 [1.20-2.59] <0.001 DCIS RT/No-treatment 0.624 1.94 [1.15-3.26] 0.003 HGSOC Test 0.553 1.38 [1.02-1.87] 0.030 ER+ BC Test 0.577 1.51 [1.00-2.28] 0.004 HNSCC All 0.603 1.92 [1.03-3.36] 0.012
Distinguishing Inverted Sinonasal Papilloma and Respiratory Epithelial Adenomatoid Hamartoma: A Single Institution Case Series
Swisher, Austin R. , Razmi, Samuel E., Sramek, Michael T. , Gomes, Pedro L., Schmitt, Alessandra, Miglani, Amar , Lal, Devyani, Marino, Michael J. , Razmi, Samuel E. , Eells, Annica C. , Razmi, Samuel , Swisher, Austin R , Gomes, Pedro L., Schmitt, Alessandra, Lal, Devyani

Mayo Clinic

International Journal of Surgical Pathology | May 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10668969261446657 | PMID 42135597 Get It

Inverted sinonasal papilloma (ISP) and respiratory epithelial adenomatoid hamartoma (REAH) are sinonasal lesions with overlapping clinical, radiographic, and histologic features, making accurate diagnosis challenging. ISP is a benign but aggressive tumor with a propensity for local destruction, recurrence, and malignant transformation, whereas REAH is a hamartomatous lesion often arising in the olfactory cleft. We present four patients with lesions initially suspected to be ISP based on intraoperative frozen section but ultimately diagnosed as REAH on permanent pathology. All patients had polypoid sinonasal masses, frequently involving or adjacent to the olfactory cleft. Intraoperative frozen sections were often inconclusive or favored ISP, reflecting the difficulty of distinguishing these entities. Histologic analysis revealed that epithelial thickness served as a key morphologic feature differentiating ISP from REAH, with REAH exhibiting ciliated glandular proliferation and ISP characterized by hyperplastic epithelium with features of columnar and squamous differentiation. These patients underscore the diagnostic pitfalls of small biopsies and frozen sections, and highlight the importance of permanent specimens and collaboration with experienced pathologists. Accurate differentiation is critical, as management strategies differ substantially: ISP requires aggressive resection and long-term surveillance, while REAH may be treated with limited excision and minimal follow-up.
Long‐term hippocampal alterations and cognitive impairment in a murine model of surgical sepsis
Cho, Dong Seong , Schmitt, R. , Ducharme, Alexandra M. , Doles, Jason D. , Schmitt, Rebecca E , Ducharme, Alexandra , Doles, Jason D , Dasgupta, Aneesha

Mayo Clinic

FEBS Open Bio | April 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/2211-5463.70240 | PMID 41992425 Get It

Cognitive impairment in sepsis survivors is a growing clinical challenge as the number of sepsis cases rise and acute mortality rates fall. It is estimated that up to 70% of sepsis patients experience cognitive dysfunction and many report persistent dysfunction post‐sepsis. Cognitive impairment is a broad term that refers to sepsis‐associated brain dysfunction or encephalopathy (SABD or SAE, respectively). While many contributors, such as inflammation, blood–brain barrier dysfunction, and extended microglial activation are implicated in SABD/SAE development, much is still unknown regarding the underlying mechanistic causes of persistent cognitive defects in sepsis survivors. Here, we employed cecal ligation and puncture (CLP) to model surgical sepsis in mice, after which mice were subjected to multiple memory function assays for up to 2 months post‐sepsis. Furthermore, single‐cell RNA sequencing and validation studies were performed with murine hippocampi to query alterations in the brain microenvironment. Our study shows that CLP mice exhibited decreased spontaneous alternation at 4 weeks and decreases in both short‐ and long‐term recognition (at 6 weeks and 2 weeks, respectively) accompanied by substantially altered cell type makeup of the hippocampus, including hippocampal neuron and pericyte loss. Finally, transcriptional alterations in the macrophage populations implicate aberrant activation in CLP survivors. In conclusion, post‐sepsis mice exhibit reduced memory capacity and altered hippocampal cell composition and transcriptional profiles. This study and associated data set will be valuable for further investigation of the underlying pathophysiology of SABD/SAE and elucidation of potential therapeutic candidates.
Molecular and clinical stratification of astroblastomas: Three distinct fusion-defined groups informing risk-adapted treatment strategies
Federico, Aniello , Schmitt-Hoffner, Felix , Fonseca, Adriana , Geisemeyer, Neal, Bruckner, Katharina , Mauermann, Monika, Sill, Martin , Stichel, Damian , Sturm, Dominik , Schüller, Ulrich , Tauziede-Espariat, Arnault, Capper, David, Abdullaev, Zied , Selt, Florian , Williamson, Lane, Miele, Evelina, Snuderl, Matija, Brandner, Sebastian, Lugt, Jasper van der , Bunt, Jens , Kolenova, Alexandra, Wilson, Yelena , Weintraub, Lauren , Spiegl-Kreinecker, Sabine, Aistleitner, Barbara, Zapotocky, Michal, Ramaswamy, Vijay, Korshunov, Andrey, Jones, Barbara C. , Kjaersgaard, Mimi, Kranendonk, Mariëtte E.G. , Haberler, Christine, Packer, R., Jäger, Natalie, Sahm, Prof Felix, Koster, J., Aldape, Kenneth, Hoff, Katja von , Gojo, Johannes , Kool, M., Varlet, Pascale , Capper, David , Selt, Florian , Antonelli, Manila , Brandner, Sebastian , Bunt, Jens , Raghunathan, Aditya , Ramaswamy, Vijay , Haberler, Christine , von Deimling, Andreas , Sahm, Felix , Aldape, Kenneth , Gojo, Johannes , Kool, Marcel , Von Hoff, Katja , Geisemeyer, Neal, Tauziède-Espariat, Arnault , Capper, David , Schrimpf, Daniel , Donson, Andrew M. , Miele, Evelina , Snuderl, Matija , Łastowska, Maria , Kramm, Christof Maria , Kolenová, Alexandra , Raghunathan, Aditya , Hansford, Jordan R. , Spiegl‐Kreinecker, Sabine , Baroni, Lorena , Zápotocký, Michal , Ramaswamy, Vijay , Korshunov, Andrey , Kjærsgaard, Mimi , Haberler, Christine , Deimling, Andreas von , Sahm, Felix , Pfister, Stefan M. , Kool, Marcel

Mayo Clinic

Neuro-Oncology | December 18, 2025 | Volume: 28 | Issue: 4 | Pages: 1005-1019

10.1093/neuonc/noaf283 | PMID 41429568 Get It

Abstract Background Astroblastomas are rare brain tumors predominantly affecting children and young adults, for which molecular subtypes and clinical management remain undefined. Methods We analyzed tumor samples, molecular profiles, and clinical data from 200 patients, classified as “Astroblastoma, MN1-altered” under WHO criteria, using DNA methylation profiling, DNA/RNA profiling/sequencing, and survival analyses. Results DNA methylation analyses identified 3 groups: Group A (n = 143, characterized by MN1::BEND2 fusions, predominantly supratentorial location, with striking female predominance and favorable survival); Group B (n = 37, epigenetically and transcriptionally closely related to Group A, but characterized by EWSR1::BEND2 fusions, with spinal and infratentorial locations and poor prognosis); and Group C (n = 20, epigenetically and transcriptionally distinct, characterized by MN1::CXXC5 fusions, exclusively supratentorially located, with favorable survival). Progression-free and overall survival were significantly shorter in Group B (5-year PFS 14%; 10-year OS 54%) compared to A (5-year PFS 47%; 10-year OS 89%) and C (5-year PFS 75%; 10-year OS 89%). Radiotherapy improved PFS in Group B (hazard ratio 0.25), while no clear benefit was identified for Groups A and C. Conclusions Astroblastoma, MN1-altered, comprises 3 molecularly and clinically distinct groups, characterized by different fusion genes, including those without MN1. These new insights, including the identification of potential predictive biomarkers like 14q/16q loss, provide a framework for the development of risk-stratified therapeutic approaches. Importantly, we identified a molecularly defined high-risk group that benefits from radiation therapy. Our findings redefine Astroblastoma as a molecularly diverse tumor type, propose a refined classification, support the development of risk-adapted therapeutic strategies and provide a rational standard of care.
Hi-c FFPE sequencing analysis is highly concordant with FISH and detects additional variants informing diagnosis and treatment in diffuse large B-cell lymphoma
Wu, Dehong , Wang, Chang , Visco, Carlo, Chiu, April , Xu, Mina L. , Tam, Wayne , Wen, Shuai, Zu, Youli , Pan, Zenggang , Bernal‐Mizrachi, Leon , Krieken, Joannes H.J.M. Van, Choi, William , Chen, Weina , Ferreri, Andrés J.M. , Moeller, Michael, Sikkink, Kristin , Schmitt, Anthony D. , Zu, Youli , Xu‐Monette, Zijun Y. , Tzankov, Alexandar , Visco, Carlo , Hsi, Eric D. , Dybkær, Karen , Wen, Shuai, Wang, Bangchen , Bhagat, Govind , Montes‐Moreno, Santiago , Ponzoni, Maurilio , Parsons, Benjamin M. , Li, Yong , Hastie, Alex R. , Young, Ken H.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3529-3529

10.1182/blood-2025-3529 Get It

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for approximately 30% of all NHL cases. DLBCL diagnosis relies on histologic examination, immunophenotyping, molecular and fluorescence in situ hybridization (FISH) analysis to differentiate it from similar NHL subtypes with overlapping morphological features, including more high-grade lymphomas like double-hit lymphoma. Because FISH is performed in a panel of single- or dual-target test format and analyzed through microscopy and manual image analysis, assessment of multiple target biomarkers can be cumbersome and expensive. As additional biomarkers for diagnosis, subtyping, prognosis, and therapeutic decision-making become available, target panels will become larger, posing additional challenges to clinical laboratories. Patients and Methods In this study, Hi-C sequencing of FFPE samples was performed to identify all genomic rearrangements by a single sequencing analysis for an unselected DLBCL case series of 159 patients, and the results were compared to FISH for the detection of clinically important variants. Results Hi-C sequencing showed superior performance compared to FISH: standard FISH for DLBCL includes testing for MYC, BCL2, and BCL6. Between FISH and Hi-C, these biomarkers were detected 105 times, of which, FISH detected 80/105 (76%) and Hi-C detected 102/105 (97%). The cohort included 4 double-hit lymphomas by FISH but Hi-C sequencing detected five. Besides DLBCL diagnostic biomarkers (MYC, BCL2, BCL6), many additional biomarkers were detected by Hi-C sequencing including variants not tested by FISH because the clinical suspicion was ambiguous and the relevant FISH probes were not used, and those not tested because the biomarkers were not thought to be common and, hence, left out of the FISH panel. In total, Hi-C sequencing detected additional biomarkers in 42 (26%) cases, including (1) variants targeted by FISH (i.e. MYC, BCL2, BCL6) but negative, (2) classification biomarkers for other lymphomas (CCND1, MALT, IRF4), and (3) those not tested because the biomarkers are not common and not included in the FISH panel. These additional biomarkers were supportive of suspected diagnosis of DLBCL versus double-hit lymphoma (24 cases), prompted reconsideration of a different diagnosis that may have led to different treatments (6 cases, e.g. mantle cell lymphoma), or biomarkers such as PDL1, ALK, and ATM which have implications for targeted therapies and/or inclusion in clinical trials (5 cases). Conclusion The Hi-C FFPE sequencing technology has the potential to improve the workflow of pathology labs for detection of a wide range of structural variants informing precision diagnosis and treatment for lymphomas.